The Medical Supply Sanctions Act of 2025 requires the President to prohibit the export of any “drug” or “prosthetic” to the Russian Federation "notwithstanding any other provision of law." The bill defines "drug" as products approved under section 505 of the FD&C Act or section 351 of the Public Health Service Act (and their components), and defines "prosthetic" as an FDA‑authorized medical device that replaces or improves a body part (including parts and accessories).
The prohibition carries a single clear termination mechanism: it ends only after the Secretary of State certifies that Russian military operations in Ukraine have ceased and Russian forces have withdrawn. The measure is compact but consequential for exporters, compliance programs, humanitarian actors, and regulators because it substitutes an across‑the‑board export ban for the more granular licensing and exceptions that typically govern medical goods.
At a Glance
What It Does
The bill directs the President to prohibit exports of any FDA‑approved drug and any FDA‑authorized prosthetic to the Russian Federation, explicitly overriding conflicting laws or exceptions. It treats components, parts, and accessories as within scope. The ban remains in force until the Secretary of State certifies Russia’s full military withdrawal from Ukraine.
Who It Affects
U.S. pharmaceutical companies, medical device manufacturers, exporters, freight forwarders, insurers, and their compliance teams will be directly affected. Federal agencies that regulate exports and public health (State, Commerce/OFAC, FDA) will need to adapt enforcement and guidance to implement the prohibition.
Why It Matters
This is a blunt sanctions tool that closes a class of medical exports rather than relying on license-by-license controls or humanitarian carve-outs. That approach shifts compliance risk, can disrupt supply chains and contracts, and places a political, single-person (Secretary of State) condition on when the restriction ends — which has operational and legal consequences for affected industries.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill creates an immediate, categorical obligation: the President must prohibit exports to the Russian Federation of drugs that have active approvals from the FDA or biologics approvals under the Public Health Service Act, and of prosthetic devices that the FDA has authorized for marketing. By using the phrase "notwithstanding any other provision of law," the text intends this prohibition to override preexisting statutory licensing regimes and exceptions rather than fit inside them.
Definitions matter here. "Drug" is limited to products with active approvals under two specific statutory regimes, and the bill expressly includes "components" of those drugs. That pulls in finished products and likely many active pharmaceutical ingredients or critical components used in manufacture, depending on how agencies interpret "component." "Prosthetic" is tethered to FDA marketing authorization and to devices that replace or improve body parts; components and accessories are also covered, which broadens scope beyond fully assembled devices.The bill does not lay out an enforcement framework, civil or criminal penalties, or a licensing process.
It also contains no explicit humanitarian or clinical‑trial exception. Practically, implementation would likely rely on existing export control and sanctions authorities (for example, Commerce Department export regulations or Treasury Department sanctions programs) but the statute itself leaves the allocation of enforcement tools and penalties to implementing agencies.
The prohibition stays in force until the Secretary of State certifies that Russia has ceased military operations in Ukraine and removed its forces, a factual determination the bill leaves to that official’s judgment without statutory verification steps.
The Five Things You Need to Know
The bill requires the President to prohibit exports of any drug with an approval under 21 U.S.C. §355 (section 505) or 42 U.S.C. §262 (section 351) to the Russian Federation.
It defines "prosthetic" as an FDA‑authorized medical device that replaces or improves a body part and explicitly includes any component, part, or accessory.
The statute uses "notwithstanding any other provision of law," signaling that the ban supersedes conflicting export laws and regulatory exceptions rather than operating alongside them.
The text contains no humanitarian, medical‑relief, or clinical‑trial exception and does not specify a licensing or waiver mechanism for covered exports.
The prohibition terminates only when the Secretary of State certifies to Congress that Russia has ceased military operations in Ukraine and removed its military forces, with no statutory standards for that certification.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Names the measure the "Medical Supply Sanctions Act of 2025." This is purely a drafting convention but signals the bill’s purpose and will be the title referenced in future citations and committee materials.
Presidential prohibition on exports
Imposes the central command: "the President shall prohibit the export of any drug or prosthetic to the Russian Federation." The mandatory language removes discretion at the statute level and instructs the executive branch to implement a categorical ban; it does not itself describe sanctions, enforcement mechanisms, or administrative procedures for doing so.
Definition of "drug" tied to FDA approvals
Limits covered drugs to those defined under 21 U.S.C. §321 and approved under section 505 (new drug approvals, NDAs) or section 351 (biologics/licensure). The provision also includes "any component thereof," which expands the reach to parts of drug products and potentially APIs, excipients, and finished‑product components—subject to agency interpretation.
Definition of "prosthetic" tied to FDA marketing authorization
Defines prosthetics as FDA‑authorized devices that replace or improve a body part and includes parts and accessories. Because the scope hinges on FDA marketing authorization, investigational devices not yet authorized are technically excluded, while marketed devices and their components fall squarely within the prohibition.
Sunset condition based on Secretary of State certification
Ends the prohibition only when the Secretary of State certifies to Congress that Russian military operations in Ukraine have ceased and Russian forces have withdrawn. The certification is the statute’s sole mechanism for termination and the bill sets no evidentiary standard or independent review process for that determination.
This bill is one of many.
Codify tracks hundreds of bills on Foreign Affairs across all five countries.
Explore Foreign Affairs in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- U.S. foreign‑policy decisionmakers seeking a clear statutory tool to cut off a class of medical exports to Russia, because the bill creates an unambiguous, country‑specific restriction that can be used as leverage.
- Sanctions‑compliance and legal advisory firms, which will see demand for new policies, opinions, audits, and implementation work as affected companies adapt to the prohibition.
- U.S. hospitals and patients who rely primarily on domestic supply lines, if manufacturers divert stock that would have been exported back to domestic markets — producing short‑term supply retention for U.S. purchasers.
Who Bears the Cost
- U.S. pharmaceutical and medical device manufacturers and exporters: they will need to halt covered exports, renegotiate contracts, manage inventory and potential breach‑of‑contract claims, and update compliance systems to reflect an absolute country ban.
- Humanitarian organizations and NGOs that ship medical supplies to conflict areas or to cross‑border relief channels, because the bill contains no explicit humanitarian or clinical‑trial exceptions and could criminalize or block shipments of covered items unless agencies create narrow waivers.
- Freight forwarders, insurers, and logistics firms that facilitate cross‑border movement: they face routing disruptions, increased compliance screening, cargo holds, and potential insurance exclusions tied to sanctioned shipments.
- Federal agencies (State, Commerce/OFAC, FDA): they will inherit ambiguity about implementation authority, licensing procedures, and enforcement resource needs, creating administrative burdens and the need for rapid regulatory guidance.
Key Issues
The Core Tension
The core tension is between achieving blunt, predictable foreign‑policy pressure by categorically cutting a class of medical exports and preserving humanitarian channels and predictable regulatory rules for complex medical supply chains: the statute’s breadth improves leverage but risks disrupting health services, complicating compliance, and transferring ambiguity about exceptions and enforcement to federal agencies.
The bill’s breadth and textual framing create two immediate implementation tensions. First, by attaching the prohibition to FDA marketing approvals and including components, the statute potentially sweeps in active pharmaceutical ingredients, spare parts for prosthetics, and accessories—items that are often indistinguishable in global supply chains.
Agencies will have to choose narrow or broad interpretive approaches; either choice creates tradeoffs between operational clarity and avoiding unintended medical shortages.
Second, the statute is silent on enforcement mechanics, penalties, and exceptions. It does not specify whether agencies should use Commerce Department export regulations, Treasury sanctions programs, criminal statutes, or a combination.
The absence of an explicit humanitarian or clinical‑trial exception raises immediate legal and reputational risks for NGOs and manufacturers that support medical relief or research. Finally, tying the sunset to a Secretary of State certification embeds a political and evidentiary judgment into the statutory clock, which may produce uncertainty for businesses and allies unsure what facts would justify termination.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.